Sanofi is a healthcare company engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company operates in the biopharmaceutical sector, focusing on Specialty Care, General Medicines, and Vaccines. Sanofi is the ninth largest pharmaceutical company globally by sales, with a presence in approximately 60 countries and its products available in more than 160 countries. Its main markets include the US, Europe, Japan, and China.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on the transformative therapies are fitusiran and efanesoctocog alfa (hemophilia); amlitelimab (Immunology & Inflammation); tolebrutinib (multiple sclerosis); and nirsevimab (prevention of respiratory syncytial virus). The company's R&D pipeline includes 80 clinical-stage projects, with 15 projects in Phase I, 31 projects in Phase II, 28 in phase III, and six projects under registration, as of December 2025. Sanofi's R&D pipeline includes projects in immunology, rare diseases, neurology, oncology, and vaccines. The company is actively engaging with external partners to access innovative scientific developments and is focused on developing first- or best-in-class medicines. Sanofi is dedicated to creating new medicines that are inspired by patient insights and grounded in exceptional scientific research. Its focus lies in providing support to the millions of individuals who are affected by neurological disorders. By harnessing revolutionary technologies, Sanofi scientists are actively working on the development of targeted therapies that have the potential to modify the course of diseases like multiple sclerosis (MS), inflammatory diseases and amyotrophic lateral sclerosis (ALS). The company has a history of innovation in the field of hematology, starting from the pioneering development of extended half-life clotting factors for the treatment of hemophilia A and B. Furthermore, the company achieved significant milestones by introducing the first approved treatments for acquired thrombotic thrombocytopenic purpura (aTTP) and cold agglutinin disease. Sanofi is deeply committed to making important advancements in the field of rare diseases, with a focus on discovering, developing, and delivering new options for individuals affected by such conditions. The dedicated teams at Sanofi are actively working on the development of innovative medicines for disorders like Fabry, Gaucher, and Pompe diseases. Additionally, the company is making significant progress towards finding new treatments for patients with acid sphingomyelinase deficiency (ASMD) to address unmet medical needs in these areas. Its research and development teams are also actively engaged in the development of vaccine antigens, which are essential molecules that stimulate the immune response in the body to fight against disease-causing pathogens. In addition to their focus on infectious diseases, Sanofi also explores the potential of vaccines in preventing chronic diseases. The company conducts R&D activities for pharmaceuticals at two operational sites located in France: Montpellier and Vitry-sur-Seine/Alfortville; two sites in the rest of Europe (Germany and Belgium); three sites in the US: Bridgewater, Cambridge, and Framingham/Waltham; and three sites located in China (Beijing, Shanghai and Chengdu). The vaccines research and development sites are in Swiftwater, Cambridge and Orlando (the US); Marcy-l’Etoile/Lyon (France); and Toronto (Canada). In FY2025, the company spent EUR7,842 million on its R&D activities, which as a percentage of revenue stood at 17.9%, and grew 6.1% YoY.